1
|
Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Ferrari F, Salviato E, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Brenner MK, Gottschalk S, Hoyos V, Locatelli F, Caruana I, Del Bufalo F. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer 2021; 9:e001930. [PMID: 33963009 PMCID: PMC8108682 DOI: 10.1136/jitc-2020-001930] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/23/2021] [Indexed: 11/04/2022] Open
Abstract
BACKGROUND Pediatric high-grade gliomas (pHGGs) are among the most common and incurable malignant neoplasms of childhood. Despite aggressive, multimodal treatment, the outcome of children with high-grade gliomas has not significantly improved over the past decades, prompting the development of innovative approaches. METHODS To develop an effective treatment, we aimed at improving the suboptimal antitumor efficacy of oncolytic adenoviruses (OAs) by testing the combination with a gene-therapy approach using a bispecific T-cell engager (BiTE) directed towards the erythropoietin-producing human hepatocellular carcinoma A2 receptor (EphA2), conveyed by a replication-incompetent adenoviral vector (EphA2 adenovirus (EAd)). The combinatorial approach was tested in vitro, in vivo and thoroughly characterized at a molecular level. RESULTS After confirming the relevance of EphA2 as target in pHGGs, documenting a significant correlation with worse clinical outcome of the patients, we showed that the proposed strategy provides significant EphA2-BiTE amplification and enhanced tumor cell apoptosis, on coculture with T cells. Moreover, T-cell activation through an agonistic anti-CD28 antibody further increased the activation/proliferation profiles and functional response against infected tumor cells, inducing eradication of highly resistant, primary pHGG cells. The gene-expression analysis of tumor cells and T cells, after coculture, revealed the importance of both EphA2-BiTE and costimulation in the proposed system. These in vitro observations translated into significant tumor control in vivo, in both subcutaneous and a more challenging orthotopic model. CONCLUSIONS The combination of OA and EphA2-BiTE gene therapy strongly enhances the antitumor activity of OA, inducing the eradication of highly resistant tumor cells, thus supporting the clinical translation of the approach.
Collapse
MESH Headings
- Adenoviridae/genetics
- Adenoviridae/metabolism
- Adenoviridae/pathogenicity
- Animals
- Antibodies, Bispecific/genetics
- Antibodies, Bispecific/metabolism
- Apoptosis
- Brain Neoplasms/genetics
- Brain Neoplasms/metabolism
- Brain Neoplasms/therapy
- Brain Neoplasms/virology
- Cell Line, Tumor
- Coculture Techniques
- Cytotoxicity, Immunologic
- Female
- Gene Expression Regulation, Neoplastic
- Genetic Therapy
- Genetic Vectors
- Glioma/genetics
- Glioma/metabolism
- Glioma/therapy
- Glioma/virology
- Humans
- Lymphocyte Activation
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Mice, Inbred NOD
- Mice, SCID
- Neoplasm Grading
- Oncolytic Virotherapy
- Oncolytic Viruses/genetics
- Oncolytic Viruses/metabolism
- Oncolytic Viruses/pathogenicity
- Receptor, EphA2/genetics
- Receptor, EphA2/metabolism
- T-Lymphocytes/immunology
- T-Lymphocytes/metabolism
- Xenograft Model Antitumor Assays
- Mice
Collapse
Affiliation(s)
- Claudia Manuela Arnone
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Vinicia Assunta Polito
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Angela Mastronuzzi
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Andrea Carai
- Neurosurgery Unit, Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | | | - Laura Antonucci
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Lucia Lisa Petrilli
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Maria Vinci
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Francesco Ferrari
- The FIRC Institute of Molecular Oncology, IFOM, Milano, Italy
- Institute of Molecular Genetics National Research Council, Pavia, Italy
| | - Elisa Salviato
- The FIRC Institute of Molecular Oncology, IFOM, Milano, Italy
| | - Marco Scarsella
- Flow Cytometry and Histology Core Facilities, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Cristiano De Stefanis
- Flow Cytometry and Histology Core Facilities, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Gerrit Weber
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Concetta Quintarelli
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Biagio De Angelis
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Malcolm K Brenner
- Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas, USA
| | - Stephen Gottschalk
- Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Valentina Hoyos
- Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas, USA
| | - Franco Locatelli
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- Department of Pediatrics, Sapienza University of Rome, Roma, Italy
| | - Ignazio Caruana
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Francesca Del Bufalo
- Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| |
Collapse
|
2
|
Weber G, Strocchio L, Del Bufalo F, Algeri M, Pagliara D, Arnone CM, De Angelis B, Quintarelli C, Locatelli F, Merli P, Caruana I. Identification of New Soluble Factors Correlated With the Development of Graft Failure After Haploidentical Hematopoietic Stem Cell Transplantation. Front Immunol 2021; 11:613644. [PMID: 33584698 PMCID: PMC7878541 DOI: 10.3389/fimmu.2020.613644] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 12/14/2020] [Indexed: 11/13/2022] Open
Abstract
Graft failure is a severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). The mechanisms involved in this phenomenon are still not completely understood; data available suggest that recipient T lymphocytes surviving the conditioning regimen are the main mediators of immune-mediated graft failure. So far, no predictive marker or early detection method is available. In order to identify a non-invasive and efficient strategy to diagnose this complication, as well as to find possible targets to prevent/treat it, we performed a detailed analysis of serum of eight patients experiencing graft failure after T-cell depleted HLA-haploidentical HSCT. In this study, we confirm data describing graft failure to be a complex phenomenon involving different components of the immune system, mainly driven by the IFNγ pathway. We observed a significant modulation of IL7, IL8, IL18, IL27, CCL2, CCL5 (Rantes), CCL7, CCL20 (MIP3a), CCL24 (Eotaxin2), and CXCL11 in patients experiencing graft failure, as compared to matched patients not developing this complication. For some of these factors, the difference was already present at the time of infusion of the graft, thus allowing early risk stratification. Moreover, these cytokines/chemokines could represent possible targets, providing the rationale for exploring new therapeutic/preventive strategies.
Collapse
Affiliation(s)
- Gerrit Weber
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Luisa Strocchio
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Francesca Del Bufalo
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Mattia Algeri
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Daria Pagliara
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Claudia Manuela Arnone
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Biagio De Angelis
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Concetta Quintarelli
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Franco Locatelli
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.,Sapienza, University of Rome, Rome, Italy
| | - Pietro Merli
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| | - Ignazio Caruana
- Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy
| |
Collapse
|
3
|
Belardinilli T, Arnone CM, Mastronuzzi A, Ceglie G, Cacchione A, Carai A, Miele E, Camassei FD, Polito VA, Stefanis CD, Quintarelli C, Angelis BD, Locatelli F, Caruana I, Del Bufalo F. TMOD-14. INNOVATIVE 3D MODEL FOR THE ESTABLISHMENT OF PRIMARY PAEDIATRIC LOW-GRADE GLIOMA (LGG) CULTURES: NEW PLATFORM FOR ADVANCED PRECLINICAL STUDIES OF INNOVATIVE AND IMMUNOTHERAPEUTIC APPROACHES. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Tamascia Belardinilli
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Claudia Manuela Arnone
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Angela Mastronuzzi
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Giulia Ceglie
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Antonella Cacchione
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Andrea Carai
- Department of Neuroscience and Neurorehabilitation, Unit of Neurosurgery, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Evelina Miele
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Francesca Diomedi Camassei
- Department of Laboratories and Immunological Diagnostics, Pathological Anatomy Service, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Vinicia Assunta Polito
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | | | - Concetta Quintarelli
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Biagio De Angelis
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Franco Locatelli
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Ignazio Caruana
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| | - Francesca Del Bufalo
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy
| |
Collapse
|
4
|
Arnone CM, Belardinilli T, Mastronuzzi A, Polito V, Cacchione A, Carai A, Camassei FD, Scarsella M, Quintarelli C, Angelis BD, Locatelli F, Caruana I, Del Bufalo F. IMMU-12. NOVEL APPROACH FOR THE TREATMENT OF PEDIATRIC HIGH-GRADE GLIOMAS WITH THE COMBINATION OF ONCOLYTIC ADENOVIRUSES AND GENE THERAPY ENCODING A BiTE DIRECTED TO THE EphA2 TUMOR ANTIGEN. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Claudia Manuela Arnone
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Tamascia Belardinilli
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Angela Mastronuzzi
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Vinicia Polito
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Antonella Cacchione
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Andrea Carai
- Department of Neuroscience and Neurorehabilitation, Unit of Neurosurgery, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Francesca Diomedi Camassei
- Department of Laboratories and Immunological Diagnostics, Pathological Anatomy Service, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Marco Scarsella
- Research Laboratories, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Concetta Quintarelli
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Biagio De Angelis
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Franco Locatelli
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Ignazio Caruana
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| | - Francesca Del Bufalo
- Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Pediatric Hospital IRCCS, Rome, Italy
| |
Collapse
|